AHI and Nexus-Vita to fast track integration
4 minute read
Shares in Advanced Human Imaging Limited (ASX:AHI) opened in positive territory after management announced that the company had signed a binding agreement with Nexus Vita Pte Ltd (Nexus-Vita), a Singapore-based health monitoring and management technology company.
Importantly, the agreement announced today it is for the completion of the Nexus-Vita application is a separate agreement and no changes have been made to the initial binding term sheet entered into with Nexus-Vita and announced to the ASX on 6 October 2020.
This deal was projected to generate annual recurring revenue of US$3.58 million for AHI.
Harking back to the agreement just struck, Nexus Vita has engaged AHI to conclude the integration of the AHI CompleteScan Face and Body Scan capabilities into its application.
Unfortunately, Nexus-Vita has been plagued over the last 6 months with rolling lockdowns in both Japan and Singapore, causing numerous delays and loss of development staff, whilst trying to complete the acquisition and development of the Nexus-Vita application.
Nexus-Vita has agreed today to pay AHI a fixed amount of USD$500,000 for the completion of the integration to be performed by the AHI development team, ending the delays and extension sought throughout the past 6 months.
From an operational perspective Nexus-Vita has completed the initial medical health monitoring, prevention and engagement platform which is now ready to have the CompleteScan integrated in readiness for release to the customers of Nexus-Vita.
Nexus Vita app addresses health management and record-keeping
Nexus-Vita has created an application for users to track and manage all facets of their health and health records.
The platform is a proprietary state-of-the-art health management and personal record keeping system in a single digital environment, allowing users to save their records (both medical and health basis) in a single, easy to access digital platform.
The data spans multiple environments from wearable data to training, nutrition and care programs, while also allowing the user to share information with their doctor, healthcare provider, personal trainer or chronic disease management specialist.
Nexus-Vita plans to substantially improve user-to-professional data sharing and management.
The group believes this will improve lifetime health, reduce the need for medical interventions, and save cost and resources for the user and health systems through its partnership with AHI and use of the integrated CompleteScan platform.
Nexus-Vita and AHI will collaborate on this final step to integrate the CompleteScan platform into all of Nexus-Vita’s verticals, commencing with an initial integration into its pre-emptive health platform using FaceScan and BodyScan.
Market ready integration to occur by August
Under the terms of the binding agreement, AHI will deliver a market-ready integration into the Nexus-Vita platform by 31 August 2021.
Commenting on these developments, Vlado Bosanac chairman and chief executive officer of AHI said, “Bringing the integration to my team will not only deliver a world class integration, but it will also negate concerns many shareholders have aired due to the rolling delays and extensions we have granted over the past 6 months.
"Nexus-Vita has never waivered from its genuine commitment to the transaction and its enthusiasm for the capture suite that the AHI technology brings to the table.
"The group understands they are losing valuable time in market due to these delays and having the AHI team conclude the integrations brings not only certainty but quality assurance.
"Nexus Vita wants to take advantage of the global need and growth that the digital health sector is experiencing.
"The world has experienced significant disruption with individuals reluctant to attend medical facilities and the compounding strain being experienced by the healthcare system worldwide as a result of the current pandemic.
"I am pleased to be working with Jeff and the Nexus-Vita team to provide the CompleteScan platform capabilities to their unique intervention, monitoring and pre-emptive health solution”.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.